Quality of life for patients with epithelial ovarian cancer

Sun, Charlotte C.; Ramírez, Pedro T.; Bodurka, Diane C.

doi:10.1038/ncponc0693

Cited by 50 publications

(65 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to the Romanian League of Cancer [4], 6,500 new breast cancer cases are diagnosed annually, and about 60% of women developing breast cancer will die of the disease. Ovarian cancer is less frequent, with a lifetime risk estimated at 1.8% about 10 years ago (recent data are not available for Romania, but it is among the most lethal cancers and is the fourth cause of cancer mortality in women [5].…”

Section: Introductionmentioning

confidence: 99%

Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population

et al. 2010

View full text Add to dashboard Cite

Breast cancer is the most common cancer in women worldwide, including Romania, where its incidence has increased significantly during the last decade. Ovarian cancer is the fourth leading cause of mortality by cancer in women. BRCA1 and BRCA2 are major cancer predisposition genes, responsible for a large percentage of hereditary breast and ovarian cancer (HBOC) families. We investigated 17 patients from unrelated HBOC families in north-eastern Romania, screening for mutations in BRCA1 and BRCA2 by mutation-specific PCR and by dideoxy sequencing. We identified four BRCA1 and two BRCA2 mutations in the 17 families. The overall mutation frequency was 41% (7/17; 5 BRCA1 and 2 BRCA2). Two mutations (BRCA1 c.2241dupC and BRCA2 c.8680C>T) were novel and not listed in the BIC database. Two recurrent BRCA1 mutations (c.5266dupC and c.181T>G), previously described among Ashkenazi Jewish and Eastern European populations, were also found. Two unclassified variants (UV) were found, one of which was novel (BRCA2 c.4589A>G). Medical follow-up for mutation carriers was implemented. Our study is the first molecular investigation of the role of the BRCA genes in breast and ovarian cancer in Romania.

show abstract

Section: Introductionmentioning

confidence: 99%

Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Therefore, when a deleterious mutation associated with a hereditary cancer predisposition syndrome is identified in an individual, it can dramatically impact the health and well being of the individual [20][21][22][23][24]. Hereditary Breast and Ovarian Cancer (HBOC) and Familial Adenomatous Polyposis (FAP) are two hereditary cancer predisposition syndromes highlighted in this present study.…”

Section: Introductionmentioning

confidence: 99%

Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes

Brandt

Tschirgi²,

Ready

et al. 2010

Familial Cancer

View full text Add to dashboard Cite

Approximately 5-10% of cancers are caused by an inherited predisposition. Individuals affected by hereditary cancer are often concerned about transmitting a predisposition to cancer to their children. Preimplantation genetic diagnosis (PGD) is a technology that allows embryos without a deleterious mutation associated with a hereditary cancer syndrome to be identified and implanted. The aim of this study is to assess the knowledge, attitudes, and clinical experience of physicians regarding PGD for hereditary cancer predisposition syndromes. Hereditary Breast and Ovarian Cancer (HBOC) and Familial Adenomatous Polyposis (FAP) are two hereditary cancer syndromes highlighted in this present study. A survey assessing physicians' attitudes, knowledge, and clinical practice was completed by a total of 373 gynecologic oncologists (GYN ONCs) and obstetrics and gynecologists (OB/GYNs). Physicians had a limited knowledge of PGD for hereditary cancer; however, physicians reported PGD was an appropriate option for patients with either HBOC or FAP. Although GYN ONCs were more likely to care for patients with hereditary cancer (P < 0.001), they were less likely than OB/GYNs to refer their patients to a PGD specialist (P = 0.004). While 80% of GYN ONCs and 91% of OB/GYNs would refer patients to a PGD specialist, clinical experience indicates that only 29% actually referred their patients. Since 68% of physicians had incorrect or limited knowledge of PGD for hereditary cancer, there is a need for additional education.

show abstract

“…Due to the lack of clinically relevant symptoms during the early phases of cancer development, the diagnosis is frequently made at advanced stages of the disease. Surgical cytoreduction and chemotherapy usually induce tumor regression; however, most patients undergo a relapse of the disease with a high mortality rate (1). Although a number of genetic lesions associated to higher risk for specific forms of EOC have been identified, only very few biomarkers that contribute to the early diagnosis and prognosis of the disease are currently available, accounting for the difficult management of this tumor type.…”

Section: Introductionmentioning

confidence: 99%

The Differential Role of L1 in Ovarian Carcinoma and Normal Ovarian Surface Epithelium

et al. 2008

View full text Add to dashboard Cite

Epithelial ovarian carcinoma (EOC) arises from the ovarian surface epithelium (OSE), a monolayer of poorly differentiated epithelial cells that lines the ovary. The molecular mechanisms underlying EOC invasion into the surrounding stroma and dissemination to the peritoneum and to retroperitoneal lymph nodes are still unclear. Here, we analyzed the expression and the functional role of the cell adhesion molecule L1 during EOC development. In patient-derived samples, L1 was expressed both in OSE and in a subset of EOC, in the latter being mostly restricted to the invasive areas of the tumors. The expression of L1 correlated significantly with poor outcome and with unfavorable clinicopathologic features of the disease. The peculiar expression pattern of L1 in normal OSE and invasive EOC raised the possibility that this adhesion molecule serves a different function in nontransformed versus neoplastic ovarian epithelial cells. Indeed, we showed that in OSE cells L1 supports cell-cell adhesion and enhances apoptosis, whereas it has no effect on cell proliferation and invasion. In contrast, L1 inhibits cell-cell adhesion and apoptosis in ovarian carcinoma cells, where it promotes malignancy-related properties, such as cell proliferation, Erk1/2-dependent and phosphoinositide 3-kinase-dependent invasion, and transendothelial migration. Interestingly, a crosstalk with the fibroblast growth factor receptor signaling is implicated in the promalignant function of L1 in tumor cells. Our findings point to L1 as an EOC biomarker correlating with poor prognosis, and highlight a switch in L1 function associated to the neoplastic transformation of ovarian epithelial cells, thus implicating L1 as a potential therapeutic target.

show abstract

Quality of life for patients with epithelial ovarian cancer

Cited by 50 publications

References 95 publications

Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population

Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population

Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes

The Differential Role of L1 in Ovarian Carcinoma and Normal Ovarian Surface Epithelium

Contact Info

Product

Resources

About